BridGene Biosciences Announces Strategic Collaboration with Takeda to Discover Small Molecule Drugs for Immunology and Neurology Targets

BridGene Eligible to Receive Upfront and Potential Milestone Payments of approximately $770 Million SAN JOSE, Calif., Feb. 25, 2025 /PRNewswire/ -- BridGene Biosciences, Inc., a leader in the discovery of small molecule drugs for traditionally "hard-to-drug" targets, announced today a...